Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats

Experimental Physiology

Volumn 93, Issue 7, 2008, Pages 817-824

  Siragy, Helmy M ^a   Xue, Chun ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ALDOSTERONE SYNTHASE; COLLAGEN TYPE 4; FAD 286; FIBRONECTIN; GLUCOSE; HORMONE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADRENALECTOMY; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME INHIBITION; GLOMERULUS; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY; NEPHRITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT;

EID: 46149104414     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2008.042085     Document Type: Article

References (32)

1. Abbate M, Zoja C, Corna D, Capitanio M, Bertani T & Remuzzi G (1998). In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9, 1213 1224.
2. Ahmad N, Romero DG, Gomez-Sanchez EP & Gomez-Sanchez CE (2004). Do human vascular endothelial cells produce aldosterone? Endocrinology 145, 3626 3629.
3. Bacher S & Schmitz ML (2004). The NF-κB pathway as a potential target for autoimmune disease therapy. Curr Pharm Des 10, 2827 2837.
4. Barnes PJ & Karin M (1997). Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336, 1066 1071.
5. Beretta-Piccoli C, Weidmann P & Fraser R (1983). Responsiveness of plasma 18-hydroxycorticosterone and aldosterone to angiotensin II or corticotropin in nonazotemic diabetes mellitus. Diabetes 32, 1 5.
6. Cronin CC, Barry D, Crowley B & Ferriss JB (1995). Reduced plasma aldosterone concentrations in randomly selected patients with insulin-dependent diabetes mellitus. Diabet Med 12, 809 815.
7. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC & Muller DN (2005). Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111, 3087 3094.
8. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E & Ishibashi S (2004). Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66, 1493 1502.
9. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF & Gomez-Sanchez EP (1997). Aldosterone biosynthesis in the rat brain. Endocrinology 138, 3369 3373.
10. Gomez-Sanchez EP, Ahmad N, Romero DG & Gomez-Sanchez CE (2005). Is aldosterone synthesized within the rat brain? Am J Physiol Endocrinol Metab 288, E342 E346.
11. Kagami S, Border WA, Miller DE & Noble NA (1994). Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93, 2431 2437.
12. Kalantarinia K, Awad AS & Siragy HM (2003). Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64, 1208 1213.
13. Luik PT, Kerstens MN, Hoogenberg K, Navis GJ & Dullaart RP (2003). Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation. Eur J Clin Invest 33, 787 793.
14. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM & Goetz FC (1984). Structural-functional relationships in diabetic nephropathy. J Clin Invest 74, 1143 1155.
15. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM & Brown L (2001). Reversal of cardiac and renal fibrosis by pirfenidine and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133, 687 694.
16. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y & Koide H (1993). mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42, 450 456.
17. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T & Ideura T (2003). Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor on non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 361, 117 124.
18. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K, Kohno M, Tamaki T, Kajiya F & Abe Y (2005). Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 45, 710 716.
19. Park IS, Kiyomoto H, Abboud SL & Abboud HE (1997). Expression of transforming growth factor-β and type IV collagen in early streptozotocin-induced diabetes. Diabetes 46, 473 480.
20. Perez GO, Lespier L, Jacobi J, Oster JR, Katz FH, Vaamonde CA & Fishman LM (1997). Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med 137, 852 855.
21. Pfeiffer A, Middelberg-Bisping K, Drewes C & Schatz H (1996). Elevated plasma levels of transforming growth factor-β1 in NIDDM. Diabetes Care 19, 1113 1117.
22. Sato A, Hayashi K, Naruse M & Saruta T (2003). Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41, 64 68.
23. Schiffrin EL, Lipman ML & Mann JF (2007). Chronic kidney disease: effects on the cardiovascular system. Circulation 116, 85 97.
24. Schott-Ohly P, Lgssiar A, Partke HJ, Hassan M, Friesen N & Gleichmann H (2004). Prevention of spontaneous and experimentally induced diabetes in mice with zinc sulfate-enriched drinking water is associated with activation and reduction of NF-κB and AP-1 in islets, respectively. Exp Biol Med 229, 1177 1185.
25. Sharma K & Ziyadeh FN (1994). Renal hypertrophy is associated with upregulation of TGF-β1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol Renal Physiol 267, F1094 F1101.
26. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B & Delcayre C (1998). Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273, 4883 4891.
27. Siragy HM, Awad A, Abadir P & Webb R (2003). The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology 144, 2229 2233.
28. Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, Mabuchi H & Takeda R (1997). Vascular aldosterone in genetically hypertensive rats. Hypertension 29, 45 48.
29. Wolf G, Haberstroh U & Neilson EG (1992). Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140, 95 107.
30. Wolf G & Ziyadeh FN (2007). Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106, 26 31.
31. Xue C & Siragy HM (2005). Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 46, 584 590.
32. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG & Seidel K (1995). Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47, 935 944.